Overview

18F-FES PET/CT in Imaging Patients With Desmoid Tumors

Status:
Terminated
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies fluorine (F)-18 16 alpha-fluoroestradiol (18F-FES) positron emission tomography (PET)/computed tomography (CT) in imaging patients with desmoid tumors. 18F-FES binds to estrogen receptors, which are present on desmoid tumors, and gives off radiation that may be detected by PET and CT scans. The PET/CT scan forms an image that may show where tumor cells with estrogen receptors can be found in the body.
Phase:
Early Phase 1
Details
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Estradiol